Citations

Clear

7552 citation(s) found for "Ku, Matthew".

Intravenous delivery of oncolytic adenovirus TILT-123 results in systemic tumor transduction and accumulation of lymphocytes.
Santos, João M. , Jalkanen, Katriina Johanna, Block, Matthew S. , Mäenpää, Johanna , Dréno, Brigitte , Schoonenberg, Annabrita, Sorsa, Suvi , Cervera, Victor, Quixabeira, Dafne C.A. , Jirovec, Elise , Clubb, James H.A. , Pakola, Santeri A. , Alanko, Tuomo , Juteau, Susanna , Adamo, Daniel A. , Monberg, Tine Juul , Ellebæk, Eva , Donia, Marco , Svane, Inge Marie , Hemminki, Akseli

Mayo Clinic

Journal of Clinical Oncology | July 11, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 2658-2658

10.1200/jco.2024.42.16_suppl.2658 Get It

2658 Background: Immune checkpoint inhibitors provide limited benefit in patients with immunologically cold tumors, characterized by a lack of T cells. This creates a niche for T cell-inducing agents such as TILT-123 (igrelimogene litadenorepvec, Ad5/3-E2F-D24-hTNFa-IRES-hIL2). While the 5/3 chimeric oncolytic adenovirus platform prompts potent immunogenic capacity per se, this virus has been armed with TNFa and IL-2 selected based on their ability to activate and attract T cells into tumors. TILT-123 capsid modification, and double selectivity devices for virus replication in cancer cells only, allow intravenous use of TILT-123. This is an important advantage over conventional oncolytic viruses whose widespread use has been hindered by the need for intratumoral injection. Methods: Here we report tumor transduction, pharmacokinetic and immune effects of a single intravenous administration of TILT-123 from three Phase 1 dose escalation clinical trials (TUNIMO-NCT04695327, TUNINTIL-NCT04217473, and PROTA-NCT05271318), with a total of 52 patients. Overall, the most common tumor types were melanoma (20), ovarian cancer (18) and sarcoma (7). In each of these trials, the first TILT-123 injection was performed intravenously, and a tumor biopsy collected 7 days later. Peripheral blood was collected before and after systemic TILT-123 treatment. No other therapy was administered concurrently. Presence of virus in blood was detected with qPCR, while presence of virus in tumor biopsies was measured with immunohistochemistry (IHC) for adenovirus proteins. Immune changes in tumors were evaluated by IHC. Results: TILT-123 was detected in the peripheral blood of all treated patients. Virus concentration was highest at 1 hour after administration, with lower levels seen 16 hours post-injection. Concurrently, IFN-γ levels increased in the patients´ serum. The lowest TILT-123 blood concentrations were observed with the lowest dose, with progressive increases in subsequent cohorts. At higher doses, TILT-123 was detected circulating in blood one week post-administration. Treatment was safe and no dose-limiting toxicity was encountered. Overall, signs of TILT-123 transduction in tumors were observed in 75% of patients evaluated in all three trials, 80% in TUNIMO patients, and 63.64% in TUNINTIL patients. Early results from PROTA suggest a positive effect of TILT-123 in tumors from all cohorts´ dosages studied. Conclusions: In summary, intravenous injection of TILT-123 results in persistence of the virus in peripheral blood for up to 7 days. Tumor transduction was observed in 75% of patients in three Phase I trials on day 8 post TILT-123 systemic administration. These data suggest that TILT-123 could be developed as an intravenous therapy. However, further increases in tumor transduction could be achieved by using multiple intravenous injections of TILT-123. Clinical trial information: NCT04695327 ; NCT04217473 ; NCT05271318 .
Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia
Rios‐Olais, Fausto Alfredo , McGary, Alyssa , Almader‐Douglas, Diana , Leis, José F., McGary, Alyssa K, Almader-Douglas, Diana, Tsang, Mazie , Buras, Matthew , Hilal, Talal

Mayo Clinic

JAMA Oncology | July 11, 2024 | Volume: 10 | Issue: 9 | Pages: 1221

10.1001/jamaoncol.2024.2122 | PMID 38990562 Get It

ImportanceMeasurable residual disease (MRD) refers to the presence of disease at low levels not detected by conventional pathologic analysis. The association of MRD status as a surrogate end point of clinical outcome in chronic lymphocytic leukemia (CLL) has not been established in the era of targeted agents. Assessing the association of MRD with progression-free survival (PFS) may improve its role as a surrogate marker and allow its use to accelerate drug development.ObjectiveTo assess the association between MRD and PFS in CLL using data from prospective clinical trials that studied targeted agents or obinutuzumab-based treatment.Data SourcesClinical studies on CLL were identified via searches of PubMed, Embase, Scopus, and Web of Science from inception through July 31, 2023.Study SelectionProspective, single-arm, and randomized clinical trials that assessed targeted agents or obinutuzumab-based treatment and reported PFS by MRD status were included. Studies with insufficient description of MRD information were excluded.Data Extraction and SynthesisStudy sample size, median patient age, median follow-up time, line of treatment, MRD detection method and time points, and survival outcomes were extracted.Main Outcomes and MeasuresAnalyses of survival probabilities and hazard ratios (HRs) were conducted for PFS according to MRD status. Meta-analyses were performed using a random-effects model.ResultsA total of 11 prospective clinical trials (9 randomized and 2 nonrandomized) including 2765 patients were analyzed. Achieving undetectable MRD (uMRD) at 0.01% was associated with an HR of 0.28 (95% CI, 0.20-0.39; P < .001) for PFS. Median PFS was not reached in both groups (uMRD vs MRD), but the estimated 24-month PFS was better in the uMRD group (91.9% [95% CI, 88.8%-95.2%] vs 75.3% [95% CI, 64.7%-87.6%]; P < .001). The association of uMRD with PFS was observed in subgroup analyses in the first-line treatment setting (HR, 0.24; 95% CI, 0.18-0.33), relapsed or refractory disease setting (HR, 0.34; 95% CI, 0.16-0.71), and trials using time-limited therapy (HR, 0.28; 95% CI, 0.19-0.40).Conclusions and RelevanceThe findings of this systematic review and meta-analysis suggest that assessing MRD status as an end point in clinical trials and as a surrogate of PFS may improve trial efficiency and potentially allow for accelerated drug registration.
Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL
Khurana, Arushi , Mwangi, Raphael , Nastoupil, Loretta J. , Farooq, Umar , Romancik, Jason T. , McDonnell, Timothy J. , Riska, Shaun M., Lossos, lzidore S., Martin, Peter W., Flowers, Christopher R. , Nowakowski, Grzegorz S. , Farooq, Umar , Romancik, Jason T , Lossos, Izidore S , Witzig, T.E. , Cerhan, James R , Maurer, Matthew , Nastoupil, Loretta J , Reagan, Patrick Michael , Kahl, Brad S. , Martin, Peter, Witzig, Thomas E. , Cerhan, James R. , Maurer, Matthew J.

Mayo Clinic

Blood Advances | July 11, 2024 | Volume: 8 | Issue: 16 | Pages: 4414-4422

10.1182/bloodadvances.2024012838 | PMID 38991126 Get It

Abstract Underrepresentation of racial and ethnic subgroups in cancer clinical trials remains a persistent challenge. Restrictive clinical trial eligibility criteria have been shown to exacerbate this problem. We previously identified that up to 24% of patients treated with standard immunochemotherapy would have been excluded from recent first-line trials in diffuse large B-cell lymphoma (DLBCL) based on 5 laboratory-based criteria. These ineligible patients had worse clinical outcomes and increased deaths related to lymphoma progression, suggesting the potential exclusion of patients who could have benefited most from the novel therapies being evaluated. Using data from the prospectively enrolled Lymphoma Epidemiology Outcomes cohort study, with demographics broadly similar to the US patients diagnosed with lymphoma, we evaluated the impact of laboratory eligibility criteria from recent first-line DLBCL trials across various racial and ethnic backgrounds. There were significant differences in the baseline laboratory values by race/ethnicity with Black/African American (AA) patients having the lowest mean hemoglobin and highest creatinine clearance. Based on recent clinical trial eligibility criteria, AA and Hispanic patients had higher rates of laboratory-based ineligibility than non-Hispanic White patients. The largest gap in the clinical outcomes between eligible and noneligible patients was noted within AA patients with an overall survival hazard ratio based on POLARIX clinical trial criteria of 4.09 (95% confidence interval, 1.83-9.14). A thoughtful approach to the utility of each criterion and cutoffs for eligibility needs to be evaluated in the context of its differential impact across various racial/ethnic groups.
Early and Late Aortic-Related Mortality and Rupture After Fenestrated-Branched Endovascular Aortic Repair of Thoracoabdominal Aortic Aneurysms: A Prospective Multicenter Cohort Study
Oderich, Gustavo S. , Huang, Ying , Harmsen, William S. , Schanzer, Andres , Timaran, Carlos H. , Schneider, Darren B. , Mendes, Bernardo C. , Eagleton, Matthew J. , Gasper, Warren J. , Sweet, Matthew P. , Lee, W. Anthony , Parodi, F. Ezequiel, Tenorio, Emanuel R , H Timaran, Carlos , Schneider, Darren B , Eagleton, Matthew J , Farber, Mark , Gasper, Warren J , Beck, Adam W , Sweet, Matthew P , Lee, W Anthony , Oderich, Gustavo S , Tenorio, Emanuel R. , Zettervall, Sara L

Mayo Clinic

Circulation | July 11, 2024 | Volume: 150 | Issue: 17 | Pages: 1343-1353

10.1161/circulationaha.123.068234 | PMID 38989575 Get It

BACKGROUND: Fenestrated-branched endovascular aortic repair (FB-EVAR) has been used as a minimally invasive alternative to open surgical repair to treat patients with thoracoabdominal aortic aneurysms (TAAAs). The aim of this study was to evaluate aortic-related mortality (ARM) and aortic aneurysm rupture after FB-EVAR of TAAAs. METHODS: Patients enrolled in 8 prospective, nonrandomized, physician-sponsored investigational device exemption studies between 2005 and 2020 who underwent elective FB-EVAR of asymptomatic intact TAAAs were analyzed. Primary end points were ARM, defined as any early mortality (30 days or in hospital) or late mortality from aortic rupture, dissection, organ or limb malperfusion attributable to aortic disease, complications of reinterventions, or aortic rupture. Secondary end points were early major adverse events, TAAA life-altering events (defined as death, permanent spinal cord injury, permanent dialysis, or stroke), all-cause mortality, and secondary interventions. RESULTS: A total of 1109 patients were analyzed; 589 (53.1%) had extent I–III and 520 (46.9%) had extent IV TAAAs. Median age was 73.4 years (interquartile range, 68.1–78.3 years); 368 (33.2%) were women. Early mortality was 2.7% (n=30); congestive heart failure was associated with early mortality (odds ratio, 3.30 [95% CI, 1.22–8.02]; P =0.01). Incidence of early aortic rupture was 0.4% (n=4). Incidence of early major adverse events and TAAA life-altering events was 20.4% (n=226) and 7.7% (n=85), respectively. There were 30 late ARMs; 5-year cumulative incidence was 3.8% (95% CI, 2.6%–5.4%); older age and extent I–III TAAAs were independently associated with late ARM (each P <0.05). Fourteen late aortic ruptures occurred; 5-year cumulative incidence was 2.7% (95% CI, 1.2%–4.3%); extent I–III TAAAs were associated with late aortic rupture (hazard ratio, 5.85 [95% CI, 1.31–26.2]; P =0.02). Five-year all-cause mortality was 45.7% (95% CI, 41.7%–49.4%). Five-year cumulative incidence of secondary intervention was 40.3% (95% CI, 35.8%–44.5%). CONCLUSIONS: ARM and aortic rupture are uncommon after elective FB-EVAR of asymptomatic intact TAAAs. Half of the ARMs occurred early, and most of the late deaths were not aortic related. Late all-cause mortality rate and the need for secondary interventions were 46% and 40%, respectively, 5 years after FB-EVAR. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02089607, NCT02050113, NCT02266719, NCT02323581, NCT00583817, NCT01654133, NCT00483249, NCT02043691, and NCT01874197.
Multicenter Study on Physician-Modified Endografts for Thoracoabdominal and Complex Abdominal Aortic Aneurysm Repair
Tsilimparis, Nikolaos , Melo, Ryan Gouveia e , Scali, Salvatore T. , Mendes, Bernardo C. , Han, Sukgu M. , Schermerhorn, Marc L. , Adam, Donald J., Malas, Mahmoud B. , Starnes, Benjamin W., Branzan, Daniela , Timaran, Carlos H. , Bertoglio, Luca , Pedro, Luís Mendes , Pyun, Alyssa J., Magee, Gregory A. , Swerdlow, Nicholas J. , Juszczak, Maciej , Patel, Rohini J. , Panuccio, Giuseppe , Sweet, Matthew P. , Becquemin, J.-P. , Canonge, Jennifer , Porras-Colón, Jésus , Giordano, Antonino , Gouveia E Melo, Ryan , Tenorio, Emanuel R , Scali, Salvatore , Mendes, Bernardo, Han, Sukgu , Schermerhorn, Marc , Farber, Mark , Kolbel, Tilo , Joseph, George , Branzan, Daniela , H Timaran, Carlos , Cieri, Enrico , Verzini, Fabio , Beck, Adam W , Chait, Jesse , Pyun, Alyssa , Magee, Gregory A , Juszczak, Maciej , Barleben, Andrew R. , Patel, Rohini , Panuccio, Giuseppe , Sweet, Matthew P , Zettervall, Sara L , Becquemin, Jean-Pierre , Canonge, Jennifer , Porras-Colón, Jésus , Dias-Neto, Marina , Giordano, Antonino , Oderich, Gustavo S , Tenorio, Emanuel R. , Kölbel, Tilo , Cochennec, Frédéric , Gomes, Vivian Carla , Dias‐Neto, Marina , Oderich, Gustavo S.

Mayo Clinic

Circulation | July 11, 2024 | Volume: 150 | Issue: 17 | Pages: 1327-1342

10.1161/circulationaha.123.068587 | PMID 38989565 Get It

BACKGROUND: Physician modified endografts (PMEGs) have been widely used in the treatment of complex abdominal aortic aneurysm and thoracoabdominal aortic aneurysm, however, previous data are limited to small single center studies and robust data on safety and effectiveness of PMEGs are lacking. We aimed to perform an international multicenter study analyzing the outcomes of PMEGs in complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms. METHODS: An international multicenter single-arm cohort study was performed analyzing the outcomes of PMEGs in the treatment of elective, symptomatic, and ruptured complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms. Variables and outcomes were defined according to the Society for Vascular Surgery reporting standards. Device modification and procedure details were collected and analyzed. Efficacy outcomes included technical success and safety outcomes included major adverse events and 30-day mortality. Follow-up outcomes included reinterventions, endoleaks, target vessel patency rates and overall and aortic-related mortality. Multivariable analysis was performed aiming at identifying predictors of technical success, 30-day mortality, and major adverse events. RESULTS: Overall, 1274 patients were included in the study from 19 centers. Median age was 74 (IQR, 68–79), and 75.7% were men; 45.7% were complex abdominal aortic aneurysms, and 54.3% were thoracoabdominal aortic aneurysms; 65.5% patients presented electively, 24.6% were symptomatic, and 9.9% were ruptured. Most patients (83.1%) were submitted to a fenestrated repair, 3.6% to branched repair, and 13.4% to a combined fenestrated and branched repair. Most patients (85.8%) had ≥3 target vessels included. The overall technical success was 94% (94% in elective, 93.4% in symptomatic, and 95.1% in ruptured cases). Thirty-day mortality was 5.8% (4.1% in elective, 7.6% in symptomatic, and 12.7% in ruptured aneurysms). Major adverse events occurred in 25.2% of cases (23.1% in elective, 27.8% in symptomatic, and 30.3% in ruptured aneurysms). Median follow-up was 21 months (5.6–50.6). Freedom from reintervention was 73.8%, 61.8%, and 51.4% at 1, 3, and 5 years; primary target vessel patency was 96.9%, 93.6%, and 90.3%. Overall survival and freedom from aortic-related mortality was 82.4%/92.9%, 69.9%/91.6%, and 55.0%/89.1% at 1, 3, and 5 years. CONCLUSIONS: PMEGs were a safe and effective treatment option for elective, symptomatic, and ruptured complex aortic aneurysms. Long-term data and future prospective studies are needed for more robust and detailed analysis.
Training and Verification Requirements for Interpretation of Cardiac CT and MRI: AJR Expert Panel Narrative Review
Morris, Michael F. , Ocazionez-Trujillo, Daniel , Ordovás, Karen , Ranganath, Praveen , Vargas, Daniel , Woodard, Pamela K. , Choi, Andrew , Rajiah, Prabhakar Shantha, Rajiah, Prabhakar , Budoff, Matthew J. , Ghoshhajra, Brian , Patel, Amit R.

Mayo Clinic

American Journal of Roentgenology | July 10, 2024 | Volume: 224 | Issue: 3 | Pages: No page available

10.2214/ajr.24.31524 | PMID 38984783 Get It

Mental Health and Autosomal Dominant Polycystic Kidney Disease: A Narrative Review
Ebrahimi, Niloufar , Chebib, Fouad T. , Sparks, Matthew A. , Lerma, Edgar V. , Golsorkhi, Mohadese , Ghozloujeh, Zohreh Gholizadeh , Abdipour, Amir , Norouzi, Sayna , Garimella, Pranav S , Chebib, Fouad T , Sparks, Matthew A , Lerma, Edgar V , Golsorkhi, Mohadese , Ghozloujeh, Zohreh Gholizadeh , Abdipour, Amir , Norouzi, Sayna , Garimella, Pranav S.

Mayo Clinic

Kidney360 | July 8, 2024 | Volume: 5 | Issue: 8 | Pages: 1200-1206

10.34067/kid.0000000000000504 | PMID 38976329 Get It

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder marked by the development of cysts in the kidneys and other organs, leading to diverse clinical manifestations, including kidney failure. The psychological burden of ADPKD is substantial, with significant contributors including pain, daily life disruptions, depression, anxiety, and the guilt associated with transmitting ADPKD to offspring. This review details the psychological impacts of ADPKD on patients, addressing how they navigate physical and emotional challenges, including pain management, genetic guilt, mood disorders, and disease acceptance. This review also underscores the need for comprehensive research into the psychological aspects of ADPKD, focusing on the prevalence and contributing factors of emotional distress and identifying effective strategies for managing anxiety and depression. Furthermore, it highlights the importance of understanding the diverse factors that influence patients' quality of life and advocates for holistic interventions to address these psychological challenges.
Effect of N ‐acetyl cysteine in children with metabolic dysfunction‐associated steatotic liver disease—A pilot study
Balagopal, Prabhakaran , Uppal, Vikas , Shah, Chetan , McGoogan, Katherine E. , Goran, Michael I. , Hossain, Jobayer , Balagopal, P Babu , Kohli, Rohit , Averill, Lauren W. , Guglielmo, Matthew D. Di

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | July 8, 2024 | Volume: 79 | Issue: 3 | Pages: 652-660

10.1002/jpn3.12312 | PMID 38973318 Get It

Abstract Background Prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), and its sequelae of more severe forms such as metabolic dysfunction‐associated steatohepatitis (MASH) is rapidly increasing in children with the rise in obesity. Successful and sustainable treatments for MASLD are lacking in children. We determined the therapeutic effect of N ‐acetyl cysteine (NAC) on biomarkers of oxidative stress, inflammation and insulin resistance (IR), liver enzymes, liver fat fraction (LFF) and liver stiffness (LS) in children with obesity and biopsy‐confirmed MASLD. Methods Thirteen children ( n = 13; age: 13.6 ± 2.8 years; NAS score >2) underwent a double‐blind, placebo‐controlled trial of NAC (either 600 or 1200 mg NAC/day) or placebo for 16 weeks. Measurements included LFF (magnetic resonance imaging), LS (ultrasound elastography), and body composition. Erythrocyte glutathione (GSH), liver enzymes, insulin, glucose, adiponectin, high‐sensitivity c‐reactive protein (hs‐CRP), and interleukin‐6 (IL‐6) were also measured. homeostasis model assessment for insulin resistance (HOMA‐IR) was calculated. Results Sixteen‐week NAC treatment improved (baseline adjusted between‐group p < .05 for all) markers of inflammation (IL‐6 and hs‐CRP), oxidative stress (GSH), and IR (HOMA‐IR) and reduced liver enzymes, LFF and LS. Body weight and body composition did not show beneficial changes. Conclusions Sixteen‐week NAC treatment was well tolerated in children with obesity and MASLD and led to improvements in oxidative stress, inflammation and IR and liver outcomes. The results from this pilot study support further investigation of NAC as a therapeutic agent in children with MASLD.
Micromagnetic Neural Stimulation and Spintronic Neural Sensing
Tonini, Denis , Hopper, Matthew S. , Goyal, Abhinav , Sanger, Zachary , Faramarzi, Sadegh , Shiao, Maple, Helden, Dusty Van , Wu, Kai , Keirstead, Susan A. , Netoff, Théoden I. , Low, Walter C. , Osborn, John, Bennet, Kevin E. , Lee, Kendall H. , Shin, Hojin , Wang, Jian-Ping , Saha, Renata , Yuen, Jason , Oh, Yoonbae , Bloom, Robert P. , Benally, Onri Jay

Mayo Clinic

2024 IEEE International Magnetic Conference - Short papers (INTERMAG Short papers) | July 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-2

10.1109/intermagshortpapers61879.2024.10576875 Get It

Ulcerative erythematous papules and plaques on the face and lower legs of a man living with HIV: a clinicopathological challenge
McKenzie, Ning C. , Hickey, Matthew D. , Sancha, Carlo De la , Coates, Sarah J. , Leslie, Kieron

Mayo Clinic

International Journal of Dermatology | July 5, 2024 | Volume: 63 | Issue: 11 | Pages: 1522-1524

10.1111/ijd.17362 | PMID 38965065 Get It

AbstractA 44‐year‐old male presented with a 2‐month history of erythematous ulcerative papules and plaques on the scalp, face, and bilateral lower legs. He had a 5‐year history of well‐controlled HIV on antiretroviral therapy and recurrent syphilis infections. His face had violaceous plaques, while bilateral ankles and calves had ulcerative lesions with necrotic centers and purple borders. The morphologies clinically mimicked pyoderma gangrenosum on the lower extremities and cutaneous lymphoma on the face. Biopsy and reactive rapid plasma reagin confirmed a diagnosis of lues maligna, and the patient was successfully treated with penicillin G benzathine.